ACAD vs LIVN
ACADIA Pharmaceuticals Inc. vs LivaNova — AI-powered side-by-side comparison
ACAD
ACADIA Pharmaceuticals Inc.
71
Buy
VS
| Metric | ACAD | LIVN |
|---|
| AI Score |
71
|
70
|
| Price |
$28.23
|
$82.25
|
| P/E Ratio |
12.55×
|
23.83×
|
| ROE |
31.9%
|
-20.2%
|
| Revenue Growth YoY |
—
|
—
|
| Gross Margin |
91.1%
|
68.2%
|
| Debt / Equity |
0.06×
|
0.27×
|
| Dividend Yield |
0.0%
|
0.0%
|
| RSI (14) |
55.3
|
60.6
|
| Beta |
0.845
|
0.872
|
| Expected Upside |
+0.4%
|
+0.8%
|
AI Committee View
Current Innellis committee reasoning for ACAD versus LIVN.
ACAD leads by 1 points.
ACAD scores 71/100 (Buy) versus LIVN at 70/100 (Buy).
ACAD Committee View
83% agreement
6 analysts
The committee is split. Analysts see this stock differently enough that the current rating reflects genuine uncertainty, not a weak signal.
Bull Case
- P/E of 12.9 is inexpensive for the broad market — Value
- ROE of 32.4% shows genuine earnings power backing the valuation — Value
- Revenue growing 47.0% YoY -- genuine top-line momentum — Growth
Bear Case
- Bollinger bandwidth of 26.0% signals elevated volatility — Risk
LIVN Committee View
80% agreement
5 analysts
The primary driver is vix regime is low -- calm backdrop supports risk-taking. Most analysts agree, and no major concerns are blocking a stronger rating.
Bull Case
- ROE of 15.4% shows genuine earnings power backing the valuation — Value
- 5 consecutive earnings beats -- consistent execution — Growth
- Quarter-over-quarter growth rate is ACCELERATING, not just positive — Growth
Bear Case
- Risk/reward is unfavorable: 5.6% downside vs 0.8% upside.